OBJECTIVES: To conduct budget impact analysis of abobotulinumtoxinA, onabotulinumtoxinA, incobotulinumtoxinA in patients with post-stroke spasticity in Russia for 1-year period. Physical therapy was used in all therapy schemes.  METHODS: A budget impact model was developed in Excel 2013 to simulate the costs of abobotulinumtoxinA, onabotulinumtoxinA, incobotulinumtoxinA. The total number of patients in Russian Federation is 287,334. According to the performed modeling using up-to-date epidemiological data only 212,126 people survive by the 1^st year of therapy. The following costs were taken into account:, the costs of pharmacotherapy, costs of inpatient and outpatient care in the Russian Federation, costs of adverse events, disability pensions, GDP loss due to post-stroke spasticity (PPS). Costs of pharmacotherapy were taken from the essential drug list and the database of drugs prices. Standard of treatment of stroke consequences developed by Ministry of Health of the Russian Federation was used for calculation of medical care costs. Costs of adverse events were calculated basing on Russian clinical guidelines and database of drugs prices. Disability pensions were taken from Russian Pension Fund database. GDP loss was based on the GDP information from World Bank. For reference, accepted exchange rate was 1 US$ = 60,29 RUB.  RESULTS: AbobotulinumtoxinA treatment in whole population of PPS patients in Russia will result in US$ 185,07 million economy for 1 year compared with onabotulinumtoxinA, US$ 183,13 million economy compared with IncobotulinumtoxinA and will result in US$ 756 economy for 1 year compared with onabotulinumtoxinA, US$ 737 economy compared with incobotulinumtoxinA per one patient.  This cost reduction is mainly attributed to decrease of GDP loss, disability pensions due to the better efficacy of this BTA drug. CONCLUSIONS: Inclusion of abobotulinumtoxinA therapy is the most cost saving treatment option in the management of post-stroke spasticity in Russia compared with other BTA medications.